Brenda S.  Furlow net worth and biography

Brenda Furlow Biography and Net Worth

SVP of Bio-Techne
Executive Vice President - General Counsel, Secretary and Chief Compliance Officer

Brenda Furlow joined the Company as Senior Vice President and General Counsel in August 2014. Before joining the Company, Ms. Furlow was affiliated with Alphatech Counsel, SC and served as general counsel to emerging growth technology companies. From 2007 to 2011, Ms. Furlow was General Counsel for TomoTherapy, Inc., a global, publicly traded company that manufactured and sold radiation therapy equipment, and from 1998 to 2007, she was General Counsel for Promega Corporation, a global life sciences company.

Ms. Furlow holds a Juris Doctor degree from University of Chicago Law School.

What is Brenda S. Furlow's net worth?

The estimated net worth of Brenda S. Furlow is at least $1.56 million as of December 7th, 2022. Ms. Furlow owns 26,092 shares of Bio-Techne stock worth more than $1,564,998 as of March 26th. This net worth approximation does not reflect any other investments that Ms. Furlow may own. Learn More about Brenda S. Furlow's net worth.

How do I contact Brenda S. Furlow?

The corporate mailing address for Ms. Furlow and other Bio-Techne executives is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. Bio-Techne can also be reached via phone at (612) 379-8854 and via email at ir@bio-techne.com. Learn More on Brenda S. Furlow's contact information.

Has Brenda S. Furlow been buying or selling shares of Bio-Techne?

Brenda S. Furlow has not been actively trading shares of Bio-Techne during the last quarter. Most recently, Brenda S. Furlow sold 800 shares of the business's stock in a transaction on Wednesday, December 7th. The shares were sold at an average price of $82.01, for a transaction totalling $65,608.00. Following the completion of the sale, the senior vice president now directly owns 26,092 shares of the company's stock, valued at $2,139,804.92. Learn More on Brenda S. Furlow's trading history.

Who are Bio-Techne's active insiders?

Bio-Techne's insider roster includes Robert Baumgartner (Director), Norman Eansor (Insider), Brenda Furlow (SVP), Amy Herr (Director), John Higgins (Director), James Hippel (CFO), Kim Kelderman (CEO, President & Director), Charles Kummeth (CEO), Roeland Nusse (Director), and Alpna Seth (Director). Learn More on Bio-Techne's active insiders.

Are insiders buying or selling shares of Bio-Techne?

In the last twelve months, insiders at the biotechnology company sold shares 2 times. They sold a total of 15,252 shares worth more than $1,157,753.28. The most recent insider tranaction occured on February, 14th when Director Amy E Herr sold 1,860 shares worth more than $122,685.60. Insiders at Bio-Techne own 3.9% of the company. Learn More about insider trades at Bio-Techne.

Information on this page was last updated on 2/14/2025.

Brenda S. Furlow Insider Trading History at Bio-Techne

See Full Table

Brenda S. Furlow Buying and Selling Activity at Bio-Techne

This chart shows Brenda S Furlow's buying and selling at Bio-Techne by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$50k$0$50kTotal Insider BuyingTotal Insider Selling

Bio-Techne Company Overview

Bio-Techne logo
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Read More

Today's Range

Now: $59.98
Low: $59.33
High: $61.86

50 Day Range

MA: $67.54
Low: $58.47
High: $78.75

2 Week Range

Now: $59.98
Low: $56.60
High: $85.57

Volume

1,454,467 shs

Average Volume

1,079,078 shs

Market Capitalization

$9.48 billion

P/E Ratio

60.59

Dividend Yield

0.53%

Beta

1.3